Literature DB >> 23686437

The spread of the J Project.

Zsuzsa Horváth1, Nima Rezaei, Ismail Reisli, Irina Tuzankina, Nurzhan Otarbayev, Panteley Popandopulo, László Maródi.   

Abstract

The J Project physician education and clinical research collaboration program was launched in 2004 in Eastern and Central Europe (ECE). In less than 10 years, it has achieved remarkable success. This project aims to increase knowledge in the field of primary immunodeficiency disorders (PID), and to improve the diagnosis and treatment of patients worldwide, particularly in countries with limited economic resources, which currently report fewer such patients than expected. In most ECE countries, gene sequencing, which can provide a definitive diagnosis of PID, still remains unavailable. By contrast, such technology is used elsewhere to detect the more than 200 PID-causing genes that have been discovered in the last three decades. Thus, PID awareness programs like the J Project remain critically important, to improve diagnostic facilities and treatment and to promote clinical research collaboration. This paper highlights the achievements of the J Project and the spread of its concepts and spirit to the countries of Western Asia.

Entities:  

Mesh:

Year:  2013        PMID: 23686437     DOI: 10.1007/s10875-013-9905-2

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  19 in total

1.  The creation and progress of the J Project in Eastern and Central Europe.

Authors:  László Maródi
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

2.  Genetic characteristics of eighty-seven patients with the Wiskott-Aldrich syndrome.

Authors:  Vera Gulácsy; Tomas Freiberger; Anna Shcherbina; Malgorzata Pac; Liudmyla Chernyshova; Tadej Avcin; Irina Kondratenko; Larysa Kostyuchenko; Tatjana Prokofjeva; Srdjan Pasic; Ewa Bernatowska; Necil Kutukculer; Jelena Rascon; Nicolae Iagaru; Cinzia Mazza; Beáta Tóth; Melinda Erdos; Mirjam van der Burg; László Maródi
Journal:  Mol Immunol       Date:  2010-12-24       Impact factor: 4.407

3.  Cytotoxic T lymphocytes mediate neuronal injury in patients with X-linked agammaglobulinemia and progressive neurodegenerative disease.

Authors:  I Tuzankina; Y Kobeleva; N Kiseleva; M Bolkov; G Reuter; L Maródi
Journal:  Allergy       Date:  2011-09-27       Impact factor: 13.146

Review 4.  Human primary immunodeficiency diseases.

Authors:  Alain Fischer
Journal:  Immunity       Date:  2007-12       Impact factor: 31.745

5.  The French national registry of primary immunodeficiency diseases.

Authors: 
Journal:  Clin Immunol       Date:  2010-05       Impact factor: 3.969

Review 6.  The demographics of primary immunodeficiency diseases across the unique ethnic groups in Iran, and approaches to diagnosis and treatment.

Authors:  Nima Rezaei; Payam Mohammadinejad; Asghar Aghamohammadi
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

Review 7.  Novel mutation of the activation-induced cytidine deaminase gene in a Tajik family: special review on hyper-immunoglobulin M syndrome.

Authors:  Seyed Alireza Mahdaviani; Armin Hirbod-Mobarakeh; Ning Wang; Asghar Aghamohammadi; Lennart Hammarström; Mohammad Reza Masjedi; Qiang Pan-Hammarström; Nima Rezaei
Journal:  Expert Rev Clin Immunol       Date:  2012-08       Impact factor: 4.473

8.  Novel sequence variation of AIRE and detection of interferon-omega antibodies in early infancy.

Authors:  Beáta Tóth; Anette S B Wolff; Zita Halász; Attila Tar; Péter Szüts; István Ilyés; Melinda Erdos; Gyula Szegedi; Eystein S Husebye; Margit Zeher; László Maródi
Journal:  Clin Endocrinol (Oxf)       Date:  2009-10-26       Impact factor: 3.478

9.  History of primary immunodeficiency diseases in iran.

Authors:  Asghar Aghamohammadi; Mostafa Moin; Nima Rezaei
Journal:  Iran J Pediatr       Date:  2010-03       Impact factor: 0.364

10.  Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry.

Authors:  Nima Rezaei; Asghar Aghamohammadi; Mostafa Moin; Zahra Pourpak; Masoud Movahedi; Mohammad Gharagozlou; Lida Atarod; Bahram Mirsaeid Ghazi; Anna Isaeian; Maryam Mahmoudi; Kamran Abolmaali; Davoud Mansouri; Saba Arshi; Naser Javaher Tarash; Roya Sherkat; Hedayat Akbari; Reza Amin; Abdolvahab Alborzi; Sara Kashef; Reza Farid; Iraj Mohammadzadeh; Mehrnaz Sadeghi Shabestari; Mohammad Nabavi; Abolhassan Farhoudi
Journal:  J Clin Immunol       Date:  2006-10-06       Impact factor: 8.542

View more
  4 in total

1.  Fifteen Years of the J Project.

Authors:  László Maródi
Journal:  J Clin Immunol       Date:  2019-05-17       Impact factor: 8.317

2.  Primary immunodeficiencies in Central and Eastern Europe-the power of networking Report on the activity of the Jeffrey Modell Foundation Centers Network in Central and Eastern Europe.

Authors:  A Sediva; M Bataneant; M Belevtsev; A Blaziene; P Ciznar; E Förster-Waldl; J Kelecic; J Marodi; E Naumova; G Nasrullayeva; K Ress; M Serban; B Sitkauskiene; B Toth; V Modell; F Modell; V Tenembaum; M Marković; T Avcin
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

3.  New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe.

Authors:  Beáta Soltész; Beáta Tóth; Nadejda Shabashova; Anastasia Bondarenko; Satoshi Okada; Sophie Cypowyj; Avinash Abhyankar; Gabriella Csorba; Szilvia Taskó; Adrien Katalin Sarkadi; Leonóra Méhes; Pavel Rozsíval; David Neumann; Liudmyla Chernyshova; Zsolt Tulassay; Anne Puel; Jean-Laurent Casanova; Anna Sediva; Jiri Litzman; László Maródi
Journal:  J Med Genet       Date:  2013-05-24       Impact factor: 6.318

4.  Recurrent, Severe Aphthous Stomatitis and Mucosal Ulcers as Primary Manifestations of a Novel STAT1 Gain-of-Function Mutation.

Authors:  Melinda Erdős; Eszter Jakobicz; Beáta Soltész; Beáta Tóth; Zsuzsanna Bata-Csörgő; László Maródi
Journal:  Front Immunol       Date:  2020-05-28       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.